These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2048231)

  • 1. Measurement of the ovarian cancer-associated antigen CA 125 in monitoring tumor burden and response to chemotherapy.
    Quaranta M; Coviello M; Donadeo A; Rella C; Lorusso V; Micelli G; Lucarelli C
    Tumori; 1991 Apr; 77(2):167-9. PubMed ID: 2048231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
    Meden H; Rath W; Teichmann A; Kuhn W
    Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
    Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA 15-3 serum levels in ovarian cancer.
    Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
    Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients.
    Hising C; Anjegård IM; Einhorn N
    Am J Clin Oncol; 1991 Apr; 14(2):111-4. PubMed ID: 2028919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA 125, placental alkaline phosphatase, and tissue polypeptide antigen in the monitoring of ovarian carcinoma. A comparative study of three different tumor markers.
    Hørding U; Toftager-Larsen K; Dreisler A; Lund B; Daugaard S; Lundvall F; Arends J; Winkel P; Rørth M
    Gynecol Obstet Invest; 1990; 30(3):178-83. PubMed ID: 2265805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.
    Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R
    Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
    Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
    Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
    Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
    Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker.
    Onetto M; Bruzzone M; Conte PF; Ruvolo M; Conio A; Chiara S; Falcone A; Bentivoglio G; Serra GE; Paganuzzi M
    Oncology; 1989; 46(2):117-22. PubMed ID: 2710476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA-125 monitoring during chemotherapy for ovarian cancer.
    Martoni A; Bellucco A; Marabini A; Orlandi C; Platé L; Bianchi D; Pannuti F
    Int J Biol Markers; 1986; 1(3):121-8. PubMed ID: 3480916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 125, CA 15.3 and CA 19.9 levels and surgical findings in patients undergoing second look operations for ovarian carcinomas.
    Barrenetxea G; Martin-Mateos M; Barzazan MJ; Montoya F; Matia JC; Rodriguez-Escudero FJ
    Eur J Gynaecol Oncol; 1990; 11(5):369-74. PubMed ID: 2097153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
    Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
    Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas.
    Molina R; Ojeda B; Filella X; Borras G; Jo J; Mas E; Lopez JJ; Ballesta A
    Tumour Biol; 1992; 13(5-6):278-86. PubMed ID: 1290025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biological tumor markers' myopia: a model with CA 125 and second-look in ovarian cancer.
    Zanaboni F; Accinelli G; Colombo P; Jelmoni G; Morandi C; Pedronetto S; Sbernini R; Bolis G
    Int J Biol Markers; 1987; 2(2):105-8. PubMed ID: 3482860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
    Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
    Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
    J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
    Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.
    Markowska J; Kopczyński Z; Manyś G; Szewierski Z
    Neoplasma; 1990; 37(6):687-92. PubMed ID: 2274087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.